Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
N Engl J Med
    June 2018
  1. GIORDANO SH
    Breast Cancer in Men.
    N Engl J Med. 2018;378:2311-2320.
    >> Share

  2. MULASI I
    The Scarlet Virus.
    N Engl J Med. 2018;378:2157-2159.
    >> Share

  3. FRANCIS PA, Pagani O, Fleming GF, Walley BA, et al
    Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1803164.
    >> Share

  4. LIPPMAN ME
    Endocrine Adjuvant Therapy for Localized Breast Cancer.
    N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMe1806130.
    >> Share

  5. SPARANO JA, Gray RJ, Makower DF, Pritchard KI, et al
    Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
    N Engl J Med. 2018 Jun 3. doi: 10.1056/NEJMoa1804710.
    >> Share

    May 2018
  6. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    >> Share

    March 2018
  7. NACHTIGALL L, Naftolin F, Keefe DL
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1265.
    >> Share

  8. CRAMER DW, Braaten K
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264-8.
    >> Share

  9. ROBERTS K, Merkatz RB, Vieira CS
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    >> Share

  10. WOOD S
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1264.
    >> Share

  11. SCHWARZ EB, Foster DG, Grossman D
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-4.
    >> Share


  12. Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2018;378:1263-1266.
    >> Share


  13. Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870-871.
    >> Share

  14. ANDERSON GM
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870.
    >> Share

    January 2018
  15. VAN DEN HEUVELEIBRINK MM, van der Kooi ALF, Wallace WHB
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:399-400.
    >> Share

  16. DONNEZ J, Dolmans MM
    Fertility Preservation in Women.
    N Engl J Med. 2018;378:400-401.
    >> Share

    December 2017
  17. TURNER NC
    Signatures of DNA-Repair Deficiencies in Breast Cancer.
    N Engl J Med. 2017;377:2490-2492.
    >> Share

  18. MORCH LS, Skovlund CW, Hannaford PC, Iversen L, et al
    Contemporary Hormonal Contraception and the Risk of Breast Cancer.
    N Engl J Med. 2017;377:2228-2239.
    >> Share

  19. DEMICHELE A, Yee D, Esserman L
    Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    N Engl J Med. 2017;377:2287-2289.
    >> Share

  20. HUNTER DJ
    Oral Contraceptives and the Small Increased Risk of Breast Cancer.
    N Engl J Med. 2017;377:2276-2277.
    >> Share

    November 2017
  21. PAN H, Gray R, Braybrooke J, Davies C, et al
    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
    N Engl J Med. 2017;377:1836-1846.
    >> Share

  22. NAROD S, Booth CM, Foulkes WD
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792.
    >> Share

  23. OIDE T, Mitsuishi T
    Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
    N Engl J Med. 2017;377:1777.
    >> Share


  24. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792-3.
    >> Share

  25. GREENE AK, Voss SD, Maclellan RA
    Liposuction for Swelling in Patients with Lymphedema.
    N Engl J Med. 2017;377:1788-1789.
    >> Share

    October 2017
  26. LEMERY S, Keegan P, Pazdur R
    First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    N Engl J Med. 2017;377:1409-1412.
    >> Share

    September 2017
  27. RAMASWAMI R, Morrow M, Jagsi R
    Contralateral Prophylactic Mastectomy.
    N Engl J Med. 2017;377:1288-1291.
    >> Share

    August 2017
  28. RUADES NINFEA JI, Burdette-Radoux S, Wood ME
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:790-1.
    >> Share

  29. SPURDLE AB, Goldgar DE, Easton DF
    More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795.
    >> Share


  30. More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795-6.
    >> Share

  31. HIZAL M, Sendur MAN, Yalcin B
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791.
    >> Share


  32. Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791-2.
    >> Share


  33. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Aug 9. doi: 10.1056/NEJMx170012.
    >> Share

    July 2017
  34. HAYMART MR, Miller DC, Hawley ST
    Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    N Engl J Med. 2017;377:203-206.
    >> Share


  35. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jul 12. doi: 10.1056/NEJMx170011.
    >> Share

    June 2017
  36. SCHWARTZ RS, Erban JK
    Timing of Metastasis in Breast Cancer.
    N Engl J Med. 2017;376:2486-2488.
    >> Share

  37. LANNIN DR, Wang S
    Are Small Breast Cancers Good because They Are Small or Small because They Are Good?
    N Engl J Med. 2017;376:2286-91.
    >> Share

  38. VON MINCKWITZ G, Procter M, de Azambuja E, Zardavas D, et al
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jun 5. doi: 10.1056/NEJMoa1703643.
    >> Share

  39. ROBSON M, Im SA, Senkus E, Xu B, et al
    Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1706450.
    >> Share

  40. MASUDA N, Lee SJ, Ohtani S, Im YH, et al
    Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    N Engl J Med. 2017;376:2147-2159.
    >> Share

    May 2017
  41. MOVASSAGH M, Mudvari P, Horvath A
    Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;376:2090-2091.
    >> Share

    January 2017
  42. PLICHTA JK, Hughes K
    Radiation-Induced Angiosarcoma after Breast-Cancer Treatment.
    N Engl J Med. 2017;376:367.
    >> Share

  43. DE GRAMONT A, Herrera A, de Gramont A
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    >> Share

  44. ARAKI K, Miyoshi Y
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    >> Share


  45. Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:289.
    >> Share

  46. BRENTNALL AR, Duffy SW, Cuzick J
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:94.
    >> Share


  47. Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-95.
    >> Share

  48. KOPANS DB
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-4.
    >> Share

  49. JATOI I, Anderson WF
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93.
    >> Share

    December 2016
  50. LYCETTE J
    Neglected - Cancer Care and Mental Health in Rural America.
    N Engl J Med. 2016;375:2220-2221.
    >> Share

  51. BLOK EJ, van de Velde CJ, Smit VT
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199.
    >> Share


  52. 70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2201.
    >> Share

  53. THEWES B, Prins J, Friedlander M
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2200.
    >> Share

    November 2016
  54. FINN RS, Martin M, Rugo HS, Jones S, et al
    Palbociclib and Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2016;375:1925-1936.
    >> Share

  55. SHERR CJ
    A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.
    N Engl J Med. 2016;375:1920-1923.
    >> Share

  56. WOLFF AC
    CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard.
    N Engl J Med. 2016;375:1993-1994.
    >> Share

    October 2016
  57. BUYSE M, Saad ED, Burzykowski T
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    >> Share


  58. Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    >> Share

  59. SANZ A, Del Valle ML
    Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    >> Share


  60. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    >> Share

  61. HARRINGTON D, Parmigiani G
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1593-4.
    >> Share

  62. JOENSUU H
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1592.
    >> Share

  63. WELCH HG, Prorok PC, O'Malley AJ, Kramer BS, et al
    Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.
    N Engl J Med. 2016;375:1438-1447.
    >> Share

  64. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2016.
    >> Share

    August 2016
  65. HUDIS CA, Dickler M
    Increasing Precision in Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2016;375:790-1.
    >> Share

  66. CARDOSO F, van't Veer LJ, Bogaerts J, Slaets L, et al
    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:717-29.
    >> Share

  67. HUNTER DJ
    Uncertainty in the Era of Precision Medicine.
    N Engl J Med. 2016;375:711-3.
    >> Share

    July 2016
  68. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    >> Share

  69. GOSS PE, Ingle JN, Pritchard KI, Robert NJ, et al
    Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    N Engl J Med. 2016;375:209-19.
    >> Share

  70. CAREY LA, Winer EP
    I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.
    N Engl J Med. 2016;375:83-4.
    >> Share

  71. RUGO HS, Olopade OI, DeMichele A, Yau C, et al
    Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    N Engl J Med. 2016;375:23-34.
    >> Share

  72. PARK JW, Liu MC, Yee D, Yau C, et al
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:11-22.
    >> Share

    June 2016
  73. MACINNIS RJ, Pike MC, Hopper JL
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403-4.
    >> Share

  74. KARAM A
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403.
    >> Share

  75. HARTMANN LC, Lindor NM
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2404.
    >> Share

  76. MENDELL JT
    Targeting a Long Noncoding RNA in Breast Cancer.
    N Engl J Med. 2016;374:2287-9.
    >> Share

  77. CHLEBOWSKI RT, Budoff MJ
    Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention.
    N Engl J Med. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016